ClouDr Group (9955) Fundamentals 2026 — Revenue Analysis | SniperIQ
ClouDr Group (9955) is a CN-listed Healthcare company in Medical - Distribution with a market capitalization of HK
ClouDr Group (9955) has a market capitalization of approximately HK
ClouDr Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
ClouDr Group runs a net profit margin of -56.9%, a gross margin of 47.8%, and an operating margin of -52.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
ClouDr Group reported revenue of ¥1.6B for fiscal year 2025, with net income of -¥924M and earnings per share (EPS) of -1.52. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
ClouDr Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
ClouDr Group carries a debt-to-equity ratio of 0.53x and a current ratio of 1.03x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ClouDr Group (9955) the key facts are: market cap HK
Get ClouDr Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.